ACRUX LIMITED — Major Shareholding Notification 2008

Apr 7, 2008

ACRUX (ASX: ACR) - ASX ANNOUNCEMENT

8 APRIL 2008

SHARE OWNERSHIP DISPUTE – FURTHER INFORMATION

Melbourne 8 April 2008: On 3 April 2008 Acrux (ASX: ACR) announced that it had been informed that the ownership of one substantial shareholding in the Company was in dispute as a result of the collapse of Opes Prime. On 7 April 2008, Australia and New Zealand Banking Group Limited announced that it had beneficial title to 14.5 million Acrux shares (approximately 9% of the issued share capital of Acrux), of which ANZ Nominees Limited is the registered holder. These shares represent the holding of Acrux non-executive director Ross Dobinson and his associated entities. The ownership of the shares remains in dispute.

About Acrux - www.acrux.com.au

• Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.

• Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.

• Acrux has one product, Estradiol MDTS[®] (EvaMist™ or Ellavie™) to treat menopause symptoms, approved by the US FDA and has the following products in clinical development:

  • Testosterone MD-Lotion[®] to treat testosterone deficiency in men

  • Testosterone MDTS[®] to treat decreased libido in women

  • Nestorone[®] MDTS[®] contraceptive sprays for women

  • An undisclosed companion animal health product

  • Fentanyl MDTS[®] to treat chronic pain

  • Nicotine MDTS[®] for smoking cessation

• Acrux has licensed worldwide rights to its technology for selected contraceptives and for an undisclosed proprietary drug to ORGANON, USA rights for Estradiol MDTS[®] to KV Pharmaceutical and for Testosterone MDTS[®] to VIVUS, and AUS/NZ distribution rights for Estradiol MDTS[®] to Aspen Pharmacare and for Testosterone MDTS[®] and Fentanyl MDTS[®] to CSL Limited. Acrux has also licensed its technology to Eli Lilly and Company for veterinary healthcare products.

==> picture [123 x 66] intentionally omitted <==

==> picture [360 x 66] intentionally omitted <==

==> picture [106 x 66] intentionally omitted <==